Genzyme to resubmit application to FDA for experimental multiple sclerosis treatment

This is a summary. To read the whole story subscribe to

Nearly four months after the Food and Drug Administration rejected a multiple sclerosis drug developed by Genzyme, citing the clinical trial’s design and a risk of serious side effects, the Cambridge biotech Monday said it will resubmit an application for approval to the agency.

Full story for subscribers.

Get the full story with unlimited access to

Just 99 cents for four weeks.